Semi-Annual Report — FY2026 H1
What Euglena Co.,Ltd. reported for the period from 2026-01-01 to 2026-12-31.
Filed 2026-08-07View the original on EDINET
How much it says
54Typical
What moved here
39named for the first time
Its own wording
39terms
Which filing this is
35/ 35newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the interim consolidated accounting period, Healthcare revenue increased, operating income and ordinary income rose, and interim net income attributable to owners of the parent reached ¥73 million, marking a return to profitability. By segment, higher Healthcare revenue and improved profitability were the main drivers, while the Biofuel and Other businesses each recorded changes in revenue and profit or loss.
Komori's summary of this document, not the document's own words.54Typical
How much this filing saysA weighted roll-up of 11 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 37 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
73
Detailed
68
Detailed
94
Very detailed
75
Very detailed
0
Almost nothing
0
Almost nothing
41
Thin
55
Typical
60
Detailed
55
Typical
73
Detailed
R&D spend3億円Money spent making new things.
Cash left over4億円Cash from the business, less what went into equipment.
Spent on equipment1億円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.